Prokop Vodička
YOU?
Author Swipe
View article: Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma
Predictive performance of the LEO comorbidity index in patients aged 80+ years with large B-cell lymphoma Open
Introduction The LEO Comorbidity Index (LCI), comprising ten equally weighted comorbidity categories (respiratory, cardiovascular, digestive, hepatic, renal, autoimmune, diabetes, cancer history, HIV, and stroke), has demonstrated prognost…
View article: Outcomes of T-cell/histocyte-rich large B-cell lymphoma (THRLBCL): An international LEO/MER and NiHiL collaborative study
Outcomes of T-cell/histocyte-rich large B-cell lymphoma (THRLBCL): An international LEO/MER and NiHiL collaborative study Open
Introduction: THRLBCL is a rare disease accounting for less than 10% of all diffuse large B-cell lymphoma (DLBCL) subtypes. THRLBCL was associated with poor outcomes in the pre-rituximab era, with limited contemporaneous data. Optimal fron…
View article: Performance of molecular classifiers relative to the international prognostic index (IPI) for overall and event-free survival in diffuse large B-cell lymphoma (DLBCL)
Performance of molecular classifiers relative to the international prognostic index (IPI) for overall and event-free survival in diffuse large B-cell lymphoma (DLBCL) Open
Over the past decade, classification systems using high-throughput genetic data have been developed to identify molecular subtypes of DLBCL. Although not a primary goal, these classifiers were also proposed as prognostic factors in their r…
View article: Validation of novel prognostic models in symptomatic Waldenström's macroglobulinemia based on real-world data
Validation of novel prognostic models in symptomatic Waldenström's macroglobulinemia based on real-world data Open
Introduction Waldenström's macroglobulinemia (WM) is a rare, indolent, IgM-producing lymphoplasmacytic lymphoma with diverse clinical outcomes. Prognostic models have evolved alongside treatment shifts from chemotherapy to chemoimmunothera…
View article: Comparable PFS in isolated parenchymal cns vs systemic relapse of DLBCL: Results from a large real-world cohort
Comparable PFS in isolated parenchymal cns vs systemic relapse of DLBCL: Results from a large real-world cohort Open
Introduction Despite therapeutic advances, a significant proportion of patients with diffuse large B-cell lymphoma (DLBCL) experience disease relapse (R). Previously, we reported a 5-year cumulative incidence of systemic relapse (Sy-R) and…
View article: Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation
Prognostic impact of diagnosis-to-treatment interval in follicular lymphoma patients treated with immunochemotherapy: Evidence from an international cohort with independent validation Open
Introduction Short diagnosis-to-treatment interval (DTI) is associated with aggressive disease biology and inferior outcomes in diffuse large B-cell lymphoma (DLBCL), and is recognized as a potential source of selection bias in clinical tr…
View article: FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis
FLIPI24 as a prognostic model in marginal zone lymphoma: Results from an international multi-cohort analysis Open
Introduction Marginal zone lymphoma (MZL) is an indolent and heterogenous disease. Several prognostic models have been proposed to assess outcomes in MZL, including FLIPI, IPI (primarily designed for overall survival [OS]), and MZL-specifi…
View article: Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-mini-CHOP
Treatment patterns in patients aged 80+ years with LBCL: Propensity score analysis reveals comparable outcomes between R-CHOP and R-mini-CHOP Open
Introduction Although chemo-free regimens are increasingly used in elderly patients with large B-cell lymphoma (LBCL), most still receive conventional chemoimmunotherapy. Patients up to 75–80 years old are usually treated with full-dose R-…
View article: Long‐Term Real‐World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results
Long‐Term Real‐World Outcomes of Primary CNS Lymphoma Patients Treated With MATRix Regimen Are Similar to IELSG32 Trial Results Open
Primary central nervous system lymphomas (PCNSL) are rare malignancies with poor survival outcomes. The IELSG32 trial demonstrated efficacy of MATRix chemoimmunotherapy followed by autologous stem cell transplantation (auto‐SCT) in PCNSL p…
View article: Circulating tumour <scp>DNA</scp> as a predictor of survival of patients with diffuse large B‐cell lymphoma in a daily practice
Circulating tumour <span>DNA</span> as a predictor of survival of patients with diffuse large B‐cell lymphoma in a daily practice Open
Circulating tumour DNA (ctDNA) is a promising biomarker for diffuse large B-cell lymphoma (DLBCL) risk stratification and treatment response assessment, but real-world studies were limited. Using a targeted sequencing approach (521-gene pa…
The journey of patients with diffuse large B-cell lymphoma: from symptoms to diagnosis Open
Symptoms of lymphomas include peripheral lymphadenopathy, B-symptoms, and other organ-specific symptoms; however, data on initial symptoms incidence in diffuse large B-cell lymphoma (DLBCL) remain limited. We aimed to investigate real-worl…
View article: Whole-body magnetic resonance imaging provides accurate staging of diffuse large B-cell lymphoma, but is less preferred by patients
Whole-body magnetic resonance imaging provides accurate staging of diffuse large B-cell lymphoma, but is less preferred by patients Open
BACKGROUND Whole-body magnetic resonance imaging (wbMRI) allows general assessment of systemic cancers including lymphomas without radiation burden. AIM To evaluate the diagnostic performance of wbMRI in the staging of diffuse large B-cell…
View article: Validation of the CNS-IPI-C Prognostic Model in Patients with Systemic DLBCL in the Real World
Validation of the CNS-IPI-C Prognostic Model in Patients with Systemic DLBCL in the Real World Open
Introduction CNS relapse in diffuse large B-cell lymphoma (DLBCL) is a rare, but mostly fatal event. The CNS International Prognostic Index (CNS-IPI) represents widely adopted prognostic model. As previously shown, there is a different CNS…
View article: BMI and Its Changes As a Predictor of Survival in DLBCL Patients
BMI and Its Changes As a Predictor of Survival in DLBCL Patients Open
Introduction The association between body mass index (BMI) at the time of diagnosis (dg) and the outcomes of patients with diffuse large B-cell lymphoma (DLBCL) remains controversial. As a systemic symptom, BMI loss presumably reflects the…
View article: The Survival Improvement of Transplant-Eligible Primary CNS Lymphoma Patients within Last 15 Years
The Survival Improvement of Transplant-Eligible Primary CNS Lymphoma Patients within Last 15 Years Open
Introduction Primary CNS lymphomas (PCNSL) are rare hematologic malignancies. In contrast to systemic lymphomas, patients with PCNSL have poor prognosis and limited access to novel therapeutic modalities. Subsequent introduction of rituxim…
View article: Circulating Tumor DNA As a Predictor of Survival of DLBCL Patients in a Daily Practice
Circulating Tumor DNA As a Predictor of Survival of DLBCL Patients in a Daily Practice Open
Introduction: Circulating tumor DNA (ctDNA) could be used as a sensitive biomarker of treatment response and outcomes in patients (pts) with lymphomas including diffuse large B-cell lymphoma (DLBCL). However, there is still limited data on…
Diagnosis to Treatment Interval Is the Most Significant Prognostic Factor Compared to Symptoms to Treatment As Well As to Contact to Treatment Intervals in DLBCL Patients Open
Background Short interval from diagnosis (i.e., biopsy) to treatment initiation (DTI) is associated with aggressive behavior of lymphomas including diffuse large B-cell lymphoma (DLBCL), and it should be considered as an inclusion criteriu…
Diffuse Large B-Cell Lymphoma (DLBCL): Early Patient Management and Emerging Treatment Options Open
Diffuse large B-cell lymphoma (DLBCL) represents a curable disease with a 60-70% chance of cure with current R-CHOP chemoimmunotherapy. However, 30-40% of patients are refractory or relapsing. Many attempts failed to improve the outcome of…
Expression of molecules of the Wnt pathway and of E‑cadherin in the etiopathogenesis of human thymomas Open
The molecular pathogenesis of thymoma remains largely unknown. It has been recently demonstrated, that activation of Wnt signaling pathway leads to increased incidence of thymoma in murine models. The present study investigated the activat…